The role of molecular staging in malignant melanoma

European Journal of Surgical Oncology

Volumn 29, Issue 4, 2003, Pages 306-314

  Prichard, R S ^a   Dijkstra, B ^a   McDermott, E W ^a   Hill, A D K ^a   O'Higgins, N J O ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Melanoma; Molecular staging; Tyrosinase reverse transcription polymerase chain reaction

Indexed keywords

MONOPHENOL MONOOXYGENASE;

BLOOD CELL; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MEDLINE; MELANOMA; NEURINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

EID: 0037636639     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2002.1366     Document Type: Review

References (89)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics 1996. CA Cancer J Clin 1996; 46: 5-28.
2. Brozena SJ, Fenske NA, Perez IR. Epidemiology of malignant melanoma, worldwide incidence and aetiological factors. Semin Surg Oncol 1993; 9: 165-7.
3. Friedman RJ, Rigel DS, Silverman MK, Kopf AW, Vossaert KA. Malignant melanoma in the 1990s. CA Cancer J Clin 1991; 41: 201-6.
4. Boring CC, Squires TS, Tong T, Montgomery S. Cancer Statistics 1994. CA Cancer J Clin 1994; 44: 7-26.
5. Katsambas A, Nicolaidou E. Cutaneous malignant melanoma and sun exposure: Recent developments in epidemiology. Arch Dermatol 1996; 132: 444-50.
6. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993; 71: 2995-3005.
7. Drepper H, BieB B, Hofherr B et al. The prognosis of patients with stage 3 melanoma. Cancer 1993; 71: 1239-46.
8. Balch CM. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001; 19: 3635-48.
9. Morton DL, Wen D, Wong JH et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-9.
10. Ross MI, Reintgen D, Balch CM. Selective lymphadenectomy: Emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993; 9: 219-23.
11. Molino A, Colombatti M, Bonetti F et al. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. Cancer 1991; 67: 1033-6.
12. Osbourne M, Wong GY, Asina S, Old LJ, Cote RJ, Rosen PP. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer 1991; 51: 2706-9.
13. Mattano LA, Moss TJ, Emerson SG. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase polymerase chain reaction. Cancer Res 1992; 52: 4701-5.
14. Eeles RA, Janssen JGW editors. Polymerase chain reaction. The techniques and its applications. Austin TX: R.G. Landes Cie, 1993.
15. Ghossein RA, Rosai J. Polymerase chain reaction in the detection of micrometastases and circulating tumour cells. Cancer 1996; 78: 10-16.
16. Johnson PWM, Burchill SA, Selby PJ. The molecular detection of circulating tumour cells. Br J Cancer 1995; 72: 268-76.
17. Burchill SA, Bradbury MF, Pittman K, Southgate J, Smith B, Selby P. Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction. Br J Cancer 1995; 71: 278-81.
18. Kwon BS, Haq AK, Pomerantz SH, Halaban R. Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl Acad Sci USA 1987; 84: 7473-7.
19. Ponnazhagan S, Hou L, Kwon BS. Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter region. J Inves Derma 1994; 102: 744-8.
20. Kell MR, Winter DC, O, Sullivan GC, Shanahan F, Redmond HP. Biological behaviour and clinical implications of micrometastases. Br J Surg 2000; 87: 1629-39.
21. Balch CM, Murad TM, Soong SJ, Ingalls AL, Richards PC, Maddox WA. Tumour thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 1979; 43: 883-8.
22. Balch CM, Soong SJ, Milton GW et al. A comparison of prognostic factors and surgical results in 1786 patients with localized (Stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982; 196: 677-84.
23. Milton GW, Shaw HM, McCarthy WH, Pearson L, Balch CM, Soong SJ. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982; 69: 108-11.
24. Reintgen DS, Cox EB, McCarthy KS Jr, Vollmer RT, Seigler HF. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983; 198: 379-85.
25. Das Gupta TK. Results of treatment of 269 patients with primary cutaneous melanoma: a five-year prospective study. Ann Surg 1977; 186: 201-9.
26. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma, III: prognostic factors in melanoma patients with lymph node metastases (Stage II). Ann Surg 1981; 193: 377-88.
27. Cohen MH, Ketcham AS, Felix EL et al. Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma. Ann Surg 1977; 186: 635-42.
28. McNeer G, Das Gupta TK. Prognosis in malignant melanoma. Surgery 1964; 56: 512-18.
29. Roses DF, Provet JA, Harris MN, Gumport SL, Dubin N. Prognosis of patients with pathological stage II cutaneous malignant melanoma. Ann Surg 1985; 201: 103-7.
30. Callery C, Cochran AJ, Roe DJ et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann Surg 1982; 196: 69-75.
31. Reintgen DS, Cruse CW, Wells K et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994; 220: 759-67.
32. Reintgen DS, Cox C, Slinglukk CL, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plas Surg 1992; 28: 45-9.
33. Cochran AJ, Wen DR, Morton DL. Occult tumour cells in lymph nodes of patients with pathological stage I melanoma. An immunohistochemical study. Am J Surg Pathol 1988; 12: 612-18.
34. Li W, Stall A, Schivers SC et al. Clinical relevance of molecular staging for melanoma. Ann Surg 2000; 231: 795-803.
35. Wang X, Heller R, VanVoorhis N et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994; 220: 768-74.
36. International Ludwig Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancer. Lancet 1990; 335: 1565-8.
37. Cho KH, Hashimoto K, Taniguchi Y et al. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 1990; 66: 765-71.
38. Walts AE, Said JW, Shintaku IP. Cytodiagnosis of malignant melanoma: immunoperoxidase staining with HMB-45 antibody as an aid to diagnosis. Am J Clin Pathol 1988; 90: 77-80.
39. Messina J, Glass F. Pathological examination of the sentinel lymph node. J Fla Med Assoc 1997; 84: 153-6.
40. Heyderman E, McCarthy JC. Epithelial membrane antigen and lymphoid cells. Lancet 1985; 1: 109.
41. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in the peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338: 1227-9.
42. Norman J, Cruse CW, Wells K et al. A redefinition of skin lymphatic drainage by lymphoscintigraphy for malignant melanoma. Am J Surg 1991; 162: 432-7.
43. Alkan S, Ross CW, Siddiqui J, Sheldon S, Hanson CA. Polymerase chain reaction detection of myl/rar-alpha in acute promyelocytic leukaemia using nested primers. Lab Invest 1993; 68: 1.
44. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of bcr-abl transcripts in chronic myeloid leukaemia patients after bone marrow transplation. Blood 1993; 82: 1929-36.
45. Fabrega S, Laporte JP, Giarratana MC et al. Polymerase chain reaction - a method for monitoring tumour cell purge by long term culture in bcr abl positive acute lymphoblastic leukaemia. Bone Marrow Transplant 1993; 11: 169-73.
46. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse transcriptase polymerase chain reaction. J Clin Oncol 1994; 12: 475-82.
47. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumour cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994; 12: 725-9.
48. Negrin RS, Pesando J. Detection of tumour cells in purged bone marrow and peripheral blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations. J Clin Oncol 1994; 12: 1021-7.
49. Lee MS, Chang KS, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA. Detection of minimal residual cells carrying the t (14; 18) by DNA sequence amplification. Science 1987; 237: 175-8.
50. Kawasaki ES, Clark SS, Coyne MS et al. Diagnosis of chronic myeloid and acute lymphocytic leukaemias by detection of leukaemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 1988; 85: 5698-702.
51. Negrin RS, Blume KG. The use of polymerase chain reaction for the detection of minimal residual malignant disease. Blood 1991; 78: 255-8.
52. Andreola S, Clementine C. Naevus cells in axillary lymph nodes from radical mastectomy specimens. Pathol Res Pract 1985; 179: 616-18.
53. Bautista NC, Cohen S, Anders KH. Benign melanocytic naevus cells in axillary lymph nodes. A prospective incidence and immunohistochemical study with literature review. Am J Clin Pathol 1994; 102: 102-8.
54. McCarthy SW, Palmer AA, Bale PM, Hirst E. Naevus cells in lymph nodes. Pathology 1974; 6: 351-8.
55. Ridolfi RL, Rosen PP, Thaler H. Naevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance. Cancer 1977; 39: 164-71.
56. Chelly J, Concordet JP, Kaplan JC, Khan A. Illegitimate transcription: Transcription of any gene in any cell type. Proc Natl Acad Sci USA 1989; 86: 2617-21.
57. Calogero A, Timmer-Bosscha H et al. Limitations of the nested reverse Transcriptase polymerase chain reaction on tyrosinase for the detection of malignant melanoma micrometastases in lymph nodes. Br J Cancer 2000; 83: 184-7.
58. Brossart P, Keilholz U, Willhauck M, Scheibenogen C, Mohler T, Hunstein. Haematogemous Spread of malignant melanoma cells in different stages of disease. J Invest Derm 1993; 101: 887-9.
59. Reinhold U, Ludtke-Handjery HC, Schnautz S, Kreysel, Abken H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumour progression. J Invest Derm 1997; 108: 166-9.
60. Battayani Z, Grob JJ, Xerri L et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995; 131: 443-7.
61. Foss AJE, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995; 72: 155-9.
62. Proebstle TM, Jiang W, Hogel J, Keilholz U, Weber L, Voit C. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br J Cancer 2000; 82: 118-23.
63. Mellado B, Colomer D, Castel T et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 1996; 14: 2091-7.
64. Farthmann B, Eberle J, Krasagakis K et al. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: Evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J Invest Derm 1998; 110: 263-7.
65. Hoon DSB, Wang Y, Dale PS et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995; 13: 2109-16.
66. Ghossein RA, Coit D, Brennan M et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res 1998; 4: 419-128.
67. Brossart P, Schmier JW, Kruger S et al. A polymerase chain reaction - based semiquantative assessment of malignant melanoma cells in peripheral blood. Can Res 1995; 4065-8.
68. Waldmann V, Deichmann M, Bock M, Jackel A, Naher H. The detection of tyrosinase-specific mRNA in bone marrow is not more sensitive than in blood for the demonstration of Micrometastatic melanoma. Br J Derm 1999; 140: 1060-4.
69. Schittek B, Blaheta HJ, Florchinger G, Sauer B, Garbe C. Increased sensitivity for the detection of malignant melanoma cells in peripheral blood using an improved protocol for reverse transcription-polymerase chain reaction. Br J Derm 1999; 141: 37-43.
70. Vormwald-Dogan V, Nickel P, Willemse M, Thorne M, Tilgen W. Prevalence of melanoma cells in peripheral blood of patients with malignant melanoma stage I-IV: Detection by polymerase chain reaction. J Invest Derm 1994; 103: 405.
71. Palmieri G, Pirastu M, Strazzullo M et al. Clinical significance of PCR-positive mRNA markers in peripheral blood and regional nodes of malignant melanoma patients. Recent Results Cancer Res 2001; 158: 200-3.
72. Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 1998; 16: 1760-9.
73. Jung FA, Buzaid AC, Ross MI et al. Evaluation of tyrosinase mRNA as a tumour marker in the blood of melanoma patients. J Clin Oncol 1997; 15: 2826-31.
74. Palmieri G, Strazzullo M, Ascierto PA, Satriano SMR, Daponta A, Castello G. Polymerase chain reaction-based detection of circulating melanoma cells as effective marker of tumour progression. J Clin Oncol 1999; 17: 304.
75. Hoon DSB, Bostick P, Kuo C et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000; 60: 2253-7.
76. Mellado B, Gutierrez L, Castel T et al. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res 1999; 5: 1843-8.
77. Kunter U, Buer J, Probst M et al. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 1996; 88: 590-4.
78. Pittman K, Burchill S, Smith B et al. Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol 1996; 7: 297-301.
79. Glaser R, Rass K, Seiter S et al. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumour marker in melanoma patients: A clinical two-center study. J Clin Oncol 1997; 15: 2818-25.
80. Weiss L. Metastatic Inefficiency. Adv Cancer Res 1990; 54: 159-211.
81. McMasters KM, Sondak VK, Lotze MT, Ross MI. Recent advances in melanoma staging and therapy. Ann Surg Oncol 1999; 6: 467-75.
82. Schivers SC, Li W, Lin J et al. The clinical relevance of molecular staging for melanoma. Recent Results Cancer Res 2001; 158: 187-99.
83. Schivers SC, Wang X, Li W et al. Molecular staging of malignant melanoma. Correlation with clinical outcome. JAMA 1998; 280: 1410-15.
84. Blaheta HJ, Ellwanger U, Schittek B et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Derm 2000; 114: 637-42.
85. Blaheta HJ, Schittek B, Breuninger H et al. Lymph node micrometastases of cutaneous melanoma: Increased sensitivity of molecular diagnosis in comparison to immunohistochemistry. Int J Cancer 1998; 79: 318-23.
86. Blaheta HJ, Schittek B, Breunninger H et al. Detection of melanoma micrometastasis in sentinel nodes by reverse transcriptase-polymerase chain reaction correlates with tumour thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol 1999; 23: 822-8.
87. Lukowsky A, Bellman B, Ringk A et al. Detection of melanoma micrometastases in the sentinel node and in the nonsentinel node by tyrosinase polymerase chain reaction. J Invest Derm 1999; 113: 554-9.
88. Hatta N, Takata M, Takehara K, Ohara K. Polymerase chain reaction and immunohistochemistry frequently detect melanoma cells in the regional lymph nodes of melanoma patients. J Clin Pathol 1998; 51: 597-601.
89. Bostick PJ, Morton DL, Turner RR et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999; 17: 3238-44.